Somatostatin receptor scintigraphy and chromogranin A assay in staging and follow-up of patients with well-differentiated neuroendocrine tumors

Nuclear Medicine Communications

Volumn 32, Issue 8, 2011, Pages 731-737

  Stokkel, Marcel P M ^a   Rietbergen, Daphne D ^a   Korse, Catharina M ^a   Taal, Babs G ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

chromogranin A; follow up; neuroendocrine tumors; somatostatin receptor scintigraphy; staging; well differentiated

Indexed keywords

CHROMOGRANIN A; SOMATOSTATIN RECEPTOR;

ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PREDICTIVE VALUE; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SYMPTOM;

ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; CHROMOGRANIN A; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; RECEPTORS, SOMATOSTATIN; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79959925773     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328347a895     Document Type: Article

References (22)

1. Reubi JC, Schä r J-C, Waser B,Wenger S, Heppeler A, Schmitt JS, Mä cke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27:273-282. (Pubitemid 30167697)
2. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WAP, Kooij PPM, Oei HY, et al. Somatostatin receptor scintigraphy with [In-111-DTPA-D-Phe1]- and [I123-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716-731. (Pubitemid 23284773)
3. Krausz Y, Keidar Z, Kogan I, Even-Sapir E, Bar-Shalom R, Engel A, et al. SPECT/CT hybrid imaging with In111-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol 2003; 59:565-573. (Pubitemid 37357615)
4. Rodrigues M, Gabriel M, Heute D, Putzer D, Griesmacher A, Virgolini I. Concordance between results of somatostatin receptor scintigraphy with In- 111-DOTA-DPhe-Thyr3-octreotide and chromogranin A assay in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008; 35:1796-1802.
5. Namwongprom S, Wong FC, Tateishi U, Kim EE, Boonyaprapa S. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastasis in carcinoid tumors. Ann Nucl Med 2008; 22:237-243. (Pubitemid 351809794)
6. Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, et al. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant welldifferentiated endocrine tumors. J Clin Oncol 2008; 26:963-970. (Pubitemid 351398091)
7. Korse CM, Tall BG, de Groot CA, Bakker RH, Bonfrer JMG. Chromogranin- A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. J Clin Oncol 2009; 27:4293-4299.
8. Welin S, Stridsberg M, Cunningham J, Granberg D, Skogseid B, Oberg K, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinol 2009; 89:302-307.
9. Korse CM, Bonfrer JM, Aaronson NK, Hart AA, Taal BG. Chromogranin A as an alternative to 5-hydroxyinoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors. Neuroendocrinology 2009; 89:296-301.
10. Stokkel MPM, Verkooijen RB, Smit JWA. Indium-111 octreotide scintigraphy for the detection of non-functioning metastases from differentiated thyroid cancer: diagnostic and prognostic value. Eur J Nucl Med Mol Imaging 2004; 31:950-957. (Pubitemid 38915649)
11. Binderup T, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, I123-MIBG scintigraphy, and F18- FDG PET. J Nucl Med 2010; 51:704-712.
12. Daniels CE, Lowe VJ, Aubry M-C, Allen MS, Jett JR. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest 2007; 131:255-260. (Pubitemid 46123001)
13. Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard A-S, Bouriel C, et al. Predictive value of F18-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med 2009; 50:858-864.
14. Buchman I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schä fer M, et al. Comparison of Ga68-DOTATOC PET and In111-DTPAOC (octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34:1617-1626. (Pubitemid 47476920)
15. Gabriel M, Decristiforo C, Kendler D, Dobrozemsky G, Heute D, Umprimny C, et al. Ga68-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48:508-518. (Pubitemid 47571404)
16. Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, et al. Ga68- DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with In111-DTPA-octreotide (octreoscan). Mol Imaging Biol 2010; prepub.
17. Khan MU, Morse M, Coleman RE. Radioiodinate metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors. Q J Nucl Med Mol Imaging 2008; 52:441-454.
18. Zuetenhorst JM, Hoefnagel CA, Boot H, Valdes Olmos RA, Taal BG. Evaluation of (111)In-pentreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002; 23:735-741. (Pubitemid 34837003)
19. Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N, et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors. J Nucl Med 2006; 47:1455-1462. (Pubitemid 47544931)
20. Koopmans KP, de Vries EG, Kemo IP, Elsinga PH, Neels OC, Sluiter WJ, et al. Staging of carcinoid tumours with F18-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 2006; 7: 728-734. (Pubitemid 44283659)
21. Arnold A, Chen Y-J, Costa F, Falconi M, Grosse D, Grossman AB, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: follow-up and documentation. Neuroendocrinol 2009; 90:227-233.
22. Oberg K, Ferone D, Kaltsas G, Knigge U-P, Taal B, Plockinger U, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy. Neuroendocrinol 2009; 90:209-213.